C-nitroso-derived nitroxyl donors

1. A compound of Formula I:

wherein:

R 1 is C1-C4 alkyl and R 2 is halosubstituted C1-C4 alkyl;

or R 1 is halosubstituted C1-C4 alkyl and R 2 is C1-C4 alkyl;

or R 1 and R 2 are each independently halosubstituted C1-C4 alkyl;

or R 1 and R 2 together form a C2-C7 alkylene chain; and

Z is a non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of aspirin, indomethacin, ibuprofen, fenoprofen, sulindac, naproxen, tolmetin, mefanamic acid, mefclofenamic acid, or a pharmaceutically acceptable salt or prodrug thereof.

2. The compound of claim 1 , wherein the compound has the following structure:

wherein:

R 1 is C1-C4 alkyl and R 2 is selected from the group consisting of CCl 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CF 3 , CF 2 CF 3 , CF 2 CF 2 CF 3 and CF 2 CF 2 CF 2 CF 3 ;

or R 1 is selected from the group consisting of CCl 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CF 3 , CF 2 CF 3 , CF 2 CF 2 CF 3 and CF 2 CF 2 CF 2 CF 3 and R 2 is C1-C4 alkyl;

or R 1 and R 2 are each independently selected from the group consisting of CCl 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CF 3 , CF 2 CF 3 , CF 2 CF 2 CF 3 and CF 2 CF 2 CF 2 CF 3 ;

or R 1 and R 2 together form a C2-C7 alkylene chain; and

Z is a non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of aspirin, indomethacin, ibuprofen, fenoprofen, sulindac, naproxen, tolmetin, mefanamic acid, mefclofenamic acid, or a pharmaceutically acceptable salt or prodrug thereof.

3. A compound of claim 2 having the structure:

or a pharmaceutically acceptable salt or prodrug thereof.

4. A composition comprising a compound of Formula I in a pharmaceutically acceptable carrier:

wherein:

R 1 is C1-C4 alkyl and R 2 is selected from the group consisting of CCl 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CF 3 , CF 2 CF 3 , CF 2 CF 2 CF 3 and CF 2 CF 2 CF 2 CF 3 ;

or R 1 is selected from the group consisting of CCl 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CF 3 , CF 2 CF 3 , CF 2 CF 2 CF 3 and CF 2 CF 2 CF 2 CF 3 and R 2 is C1-C4 alkyl;

or R 1 and R 7 are each independently selected from the group consisting of CCl 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CF 3 , CF 2 CF 3 , CF 2 CF 2 CF 3 and CF 2 CF 2 CF 2 CF 3 ;

or R 1 and R 2 together form a C2-C7 alkylene chain; and

R 1 and R 2 together form a C3-C6 alkylene chain; and

Z is a non-steroidal anti-inflammatory drug (NSAID);

or a pharmaceutically acceptable salt thereof.

5. A method of treating a cardiovascular disorder in a subject in need thereof, comprising administering said subject a treatment-effective amount of a compound of Formula I:

wherein:

R 1 is C1-C4 alkyl and R 2 is selected from the group consisting of CCl 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CF 3 , CF 2 CF 3 , CF 2 CF 2 CF 3 and CF 2 CF 2 CF 2 CF 3 ;

or R 1 is selected from the group consisting of CCl 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CF 3 , CF 2 CF 3 , CF 2 CF 2 CF 3 and CF 2 CF 2 CF 2 CF 3 and R 2 is C1-C4 alkyl;

or R 1 and R 2 are each independently selected from the group consisting of CCl 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CF 3 , CF 2 CF 3 , CF 2 CF 2 CF 3 and CF 2 CF 2 CF 2 CF 3 ;

or R 1 and R 2 together form a C2-C7 alkylene chain; and

R1 and R2 together form a C3-C6 alkylene chain; and

Z is a non-steroidal anti-inflammatory drug (NSAID);

or a pharmaceutically acceptable salt thereof.

6. The method of claim 5 , wherein said cardiovascular disorder is congestive heart failure.

7. The method of claim 5 , further comprising concurrently administering a beta blocker to said subject in a treatment-effective amount.

8. A method of treating gastrointestinal side effects associated with NSAID treatment in a subject in need thereof, comprising administering said subject a treatment-effective amount of a compound of Formula I:

wherein:

R 1 is C1-C4 alkyl and R 2 is selected from the group consisting of CCl 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CF 3 , CF 2 CF 3 , CF 2 CF 2 CF 3 and CF 2 CF 2 CF 2 CF 3 ;

or R 1 is selected from the group consisting of CCl 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CF 3 , CF 2 CF 3 , CF 2 CF 2 CF 3 and CF 2 CF 2 CF 2 CF 3 and R 2 is C1-C4 alkyl;

or R 1 and R 2 are each independently selected from the group consisting of CCl 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CF 3 , CF 2 CF 3 , CF 2 CF 2 CF 3 and CF 2 CF 2 CF 2 CF 3 ;

or R 1 and R 2 together form a C2-C7 alkylene chain; and

R1 and R2 together form a C3-C6 alkylene chain; and

Z is a non-steroidal anti-inflammatory drug (NSAID);

or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition for treating congestive heart failure, comprising, in combination, a pharmaceutically acceptable carrier and a treatment effective amount of a compound of Formula (III):

wherein:

R 1 is C1-C4 alkyl and R 2 is selected from the group consisting of CCl 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CF 3 , CF 2 CF 3 , CF 2 CF 2 CF 3 and CF 2 CF 2 CF 2 CF 3 ;

or R 1 is selected from the group consisting of CCl 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CF 3 , CF 2 CF 3 CF 2 CF 7 CF 3 and CF 2 CF 2 CF 2 CF 3 and R 2 is C1-C4 alkyl;

or R 1 and R 2 are each independently selected from the group consisting of CCl 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CF 3 , CF 2 CF 3 , CF 2 CF 2 CF 3 and CF 2 CF 2 CF 9 CF 3 ;

R 3 is C1-C5 alkyl, haloalkyl or aryl,

or a pharmaceutically acceptable salt or prodrug thereof.

10. The composition of claim 9 , wherein said cardiovascular disorder is congestive heart failure.

11. The composition of claim 9 wherein said composition is an injectable composition.

12. The composition of claim 9 wherein said composition is tablet or capsule.

13. The composition of claim 9 , wherein said compound is selected from the group consisting of:

or a pharmaceutically acceptable salt or prodrug thereof.

14. A method of treating congestive heart failure in a subject in need thereof, comprising administering said subject a treatment effective amount of a compound of Formula (III):

wherein:

R 1 is C1-C4 alkyl and R 2 is selected from the group consisting of CCl 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CF 3 , CF 2 CF 3 , CF 2 CF 2 CF 3 and CF 2 CF 2 CF 2 CF 3 ;

or R 1 is selected from the group consisting of CCl 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CF 3 , CF 2 CF 3 , CF 2 CF 2 CF 3 and CF 2 CF 2 CF 2 CF 3 and R 2 is C1-C4 alkyl;

or R 1 and R 2 are each independently selected from the group consisting of CCl 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CF 3 , CF 2 CF 3 CF 2 CF 2 CF 3 and CF 2 CF 2 CF 2 CF 3 ;

or R 1 and R 2 together form a C2-C7 alkylene chain; and

R 3 is C1-C5 alkyl, haloalkyl or aryl,

or a pharmaceutically acceptable salt or prodrug thereof.

15. The method of claim 14 , further comprising concurrently administering a beta blocker to said subject in a treatment effective amount.

16. The method of claim 14 , wherein said compound is selected from the group consisting of:

or a pharmaceutically acceptable salt or prodrug thereof.

17. The method of claim 14 wherein said congestive heart failure is caused by coronary artery disease, myocardial infarction, high blood pressure, heart valve disease, congenital heart defects, endocarditis, myocarditis, or any combination thereof.

18. The method of claim 14 , wherein said administering step is carried out by parenteral injection or oral administration.